What is the treatment for Clostridioides (C.) difficile infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Clostridioides difficile Infection

First-Line Treatment for Initial Episodes

Oral vancomycin 125 mg four times daily for 10 days is the recommended first-line treatment for all initial C. difficile infections, regardless of disease severity. 1, 2

Treatment Options by Severity

Non-Severe CDI:

  • Vancomycin 125 mg orally four times daily for 10 days is preferred for all cases 1, 2
  • Metronidazole 500 mg orally three times daily for 10 days may be used as an alternative for non-severe cases only, though it is inferior to vancomycin 1, 2, 3
  • Fidaxomicin 200 mg orally twice daily for 10 days is an effective alternative with lower recurrence rates 1, 2, 4

Severe CDI (defined by WBC >15 × 10⁹/L, serum albumin <30 g/L, or creatinine rise ≥1.5 times baseline):

  • Vancomycin 125 mg orally four times daily for 10 days is the treatment of choice 1, 2, 3
  • Fidaxomicin 200 mg orally twice daily for 10 days is an effective alternative with demonstrated lower recurrence rates 1, 2

Fulminant CDI (with hypotension, shock, ileus, toxic megacolon, or peritonitis):

  • Vancomycin 500 mg orally four times daily PLUS intravenous metronidazole 500 mg three times daily 1, 2
  • When oral administration is not possible, use vancomycin 500 mg in 100 mL normal saline four times daily via nasogastric tube or retention enema, combined with IV metronidazole 1
  • Obtain early surgical consultation for patients with systemic toxicity, perforation, or toxic megacolon 1, 2, 3

Treatment of Recurrent CDI

First Recurrence:

  • Vancomycin 125 mg four times daily for 10 days, especially if metronidazole was used initially 1, 2
  • Fidaxomicin 200 mg twice daily for 10 days is preferred when vancomycin was used for the first episode, due to lower recurrence rates 1, 2
  • Avoid metronidazole for recurrent episodes due to lower sustained response rates and risk of cumulative neurotoxicity 1, 2

Second and Subsequent Recurrences:

  • Vancomycin tapered and pulsed regimen: 125 mg four times daily for 10-14 days, then twice daily for 7 days, then once daily for 7 days, then every 2-3 days for 2-8 weeks 1
  • Fecal microbiota transplantation (FMT) is recommended for multiple recurrences that have failed appropriate antibiotic treatments 1, 2
  • Bezlotoxumab (monoclonal antibody against C. diff toxin B) may prevent recurrences in high-risk patients 2

Pediatric Treatment (≥6 months of age)

Non-Severe or First Recurrence:

  • Metronidazole 7.5 mg/kg/dose (max 500 mg) OR vancomycin 10 mg/kg/dose (max 125 mg) four times daily for 10 days 1
  • For children ≥12.5 kg who can swallow tablets: fidaxomicin 200 mg twice daily for 10 days 4

Severe or Fulminant:

  • Vancomycin 10 mg/kg/dose (max 500 mg) every 8 hours for 10 days, with or without IV metronidazole 1

Multiple Recurrences:

  • Vancomycin extended regimen (same tapering schedule as adults, weight-adjusted) 1
  • Consider FMT 1

Critical Management Principles

Essential Adjunctive Measures:

  • Discontinue the inciting antibiotic as soon as clinically possible to reduce recurrence risk 1, 2
  • Avoid antiperistaltic agents and opiates 3
  • Hand hygiene must be performed with soap and water, NOT alcohol-based sanitizers, as alcohol does not kill C. difficile spores 1, 2

Monitoring:

  • Assess clinical response within 3 days of treatment initiation 3
  • Treatment failure is defined as absence of improvement after 3-5 days 3

Important Caveats

Metronidazole Limitations:

  • Should be limited to initial episodes of non-severe CDI only 1
  • Never use for severe or recurrent CDI due to lower efficacy 2
  • Avoid repeated or prolonged courses due to risk of cumulative and potentially irreversible neurotoxicity 1, 2

Fidaxomicin Considerations:

  • Higher cost but reduces recurrence rates compared to vancomycin 1
  • Particularly valuable in patients at high risk for recurrence 1
  • May reduce risk of vancomycin-resistant bacteria acquisition compared to vancomycin 1

Surgical Intervention:

  • Subtotal colectomy with end ileostomy is the established procedure for systemic toxicity, perforation, or toxic megacolon 1
  • Loop ileostomy with colonic lavage is emerging as a colon-salvage alternative 1
  • Surgery should be performed before colitis becomes very severe, ideally before significant clinical deterioration 3

References

Guideline

Treatment of Clostridioides difficile Infection (C. diff)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Clostridioides difficile and Escherichia coli Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Clostridioides difficile Colitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.